Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of “Hold” by Brokerages

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) have been given an average recommendation of “Hold” by the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $4.75.

A number of equities research analysts have recently issued reports on the company. Mizuho initiated coverage on Century Therapeutics in a research note on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a report on Monday, April 6th. Zacks Research lowered shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. HC Wainwright increased their price target on shares of Century Therapeutics from $2.00 to $5.00 and gave the company a “buy” rating in a research note on Tuesday, April 21st. Finally, Leerink Partners set a $2.00 price objective on shares of Century Therapeutics and gave the company a “market perform” rating in a research report on Friday, March 13th.

Hedge Funds Weigh In On Century Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in shares of Century Therapeutics in the first quarter valued at approximately $29,000. Quadrant Private Wealth Management LLC increased its holdings in shares of Century Therapeutics by 31.0% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after acquiring an additional 4,736 shares during the last quarter. Prudential Financial Inc. bought a new stake in Century Therapeutics in the 2nd quarter valued at $25,000. OMERS ADMINISTRATION Corp bought a new stake in Century Therapeutics in the 1st quarter valued at $108,000. Finally, Cannon Global Investment Management LLC acquired a new stake in Century Therapeutics during the 1st quarter valued at $111,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Price Performance

IPSC stock remained flat at $2.43 during midday trading on Friday. 839,792 shares of the company’s stock traded hands, compared to its average volume of 1,979,832. The business has a fifty day moving average price of $2.28 and a two-hundred day moving average price of $2.07. Century Therapeutics has a 12-month low of $0.44 and a 12-month high of $3.04. The firm has a market cap of $438.25 million, a PE ratio of -2.13 and a beta of 1.55.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, May 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. As a group, equities research analysts forecast that Century Therapeutics will post -0.43 earnings per share for the current fiscal year.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.